New Issue: Innogenetics raises €34.52 million in private placement of shares

By Sheri Kasprzak

Atlanta, March 24 - Innogenetics NV said it has wrapped a private placement of stock for €34,518,726.

The company sold 2,660,216 shares at €12.60 each to institutional investors and 69,784 shares at €14.33 each to CRI BVBA, one of its shareholders.

The deal is expected to close March 31.

KBC Securities was the placement agent.

Based in Gent, Belgium, Innogenetics is a biopharmaceutical company focused on diagnostic and therapeutic vaccines. The proceeds from the deal will be used to strengthen the company's specialty diagnostics business.

Issuer:	Innogenetics NV
Issue:	Stock
Amount:	€33,518,722
Shares:	2,660,216
Price:	€12.60
Warrants:	No
Placement agent:	KBC Securities
Announcement date:	March 24
Settlement date:	March 31
Stock price:	€13.80 at close March 24
Issuer:	Innogenetics NV
Issue:	Stock
Amount:	€1,000,004
Shares:	69,784
Price:	€14.33
Warrants:	No
Placement agent:	KBC Securities
Investor:	CRI BVBA
Announcement date:	March 24
Settlement date:	March 31
Stock price:	€13.80

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.